Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.65 |
| ▸ | MC4R | P32245 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1639608 | 0.85 | SIGMAR1 (0.65) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL2941482 | 0.85 | SIGMAR1 (0.65) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL159371 | 0.82 | SIGMAR1 (0.61) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL7373892 | 0.80 | MC4R (0.70) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL8188324 | 0.79 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL576868 | 0.79 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL242970 | 0.79 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL1415730 | 0.79 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL2489199 | 0.79 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL1041303 | 0.79 | SIGMAR1 (1.00) | SIGMAR1MC4RDRD4LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256464-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2022-05-11 | — | — | EP | claimed |
| US-10004728-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-06-26 | — | — | US | claimed |
| US-20170119753-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-05-04 | — | — | US | claimed |
| US-9579314-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-02-28 | — | — | US | claimed |
| US-20160235734-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-08-18 | — | — | US | claimed |
| US-20160046574-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-18 | — | — | US | claimed |
| US-20140038943-A1 | SEROTONIN RECEPTOR MODULATOR | JANSSEN PHARMACEUTICA NV (US) | 2014-02-06 | — | — | US | claimed |
| US-8642583-B2 | Serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-04 | — | — | US | claimed |
| US-20110207714-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | claimed |
| WO-2010059393-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-27 | — | — | WO | claimed |
| CN-100450483-C | stable pharmaceutical composition containing calcium blocker | SANKYO CO (JP) | 2009-01-14 | — | — | CN | claimed |
| CN-1436077-A | stable pharmaceutical composition containing calcium blocker | SANKYO CO (JP) | 2003-08-13 | — | — | CN | claimed |
| US-20030073670-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | SANKYO COMPANY, LIMITED (JP) | 2003-04-17 | — | — | US | claimed |
| EP-1285655-A1 | STABILIZED PHARMACEUTICAL COMPOSITIONS CONTAINING CALCIUM CHANNEL BLOCKERS | Sankyo Company, Limited (JP) | 2003-02-26 | — | — | EP | claimed |
| EP-0714299-B1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2002-04-24 | — | — | EP | claimed |
| US-5665719-A | Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists | MERCK & CO., INC. (US) | 1997-09-09 | — | — | US | claimed |
| WO-2023141866-A1 | PYRAZOLOPYRIMIDINES AS MODULATORS OF SPERMINE OXIDASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | WO | disclosed |
| CN-116322692-A | Autotaxin inhibitor compounds | 日东制药株式会社 | 2023-06-23 | — | — | CN | disclosed |
| EP-0714299-A1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-06-05 | — | — | EP | disclosed |
| WO-1995002405-A1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235734-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | SIGMAR1 231/4885MC4R 353/4885DRD4 1613/4885 |
| US-20140038943-A1 | SEROTONIN RECEPTOR MODULATOR | HTR2C, HTR2A, HTR1A | SIGMAR1 170/4885MC4R 101/4885DRD4 228/4885 |
| US-20160046574-A1 | SEROTONIN RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | SIGMAR1 173/4885MC4R 88/4885DRD4 228/4885 |
| US-10004728-B2 | Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | SIGMAR1 231/4885MC4R 353/4885DRD4 1613/4885 |
| US-20110207714-A1 | SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR2C | SIGMAR1 116/4885MC4R 127/4885DRD4 343/4885 |
| US-20030073670-A1 | Stabilized pharmaceutical compositions containing a calcium channel blocker | CACNA1S, CACNA1C, CACNA1D | SIGMAR1 743/4885MC4R 1843/4885DRD4 463/4885 |
| US-20170119753-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | SIGMAR1 231/4885MC4R 353/4885DRD4 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.